PTC Therapeutics PTCT Translarna1 — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: PTC Therapeutics’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about PTC Therapeutics's translarna1 — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is PTC Therapeutics's translarna1 — revenue?
- PTC Therapeutics (PTCT) reported translarna1 — revenue of $58.82M in Q4 2025.
- How has PTC Therapeutics's translarna1 — revenue changed year-over-year?
- PTC Therapeutics's translarna1 — revenue decreased by 26.7% year-over-year, from $80.27M to $58.82M.
- What is the long-term trend for PTC Therapeutics's translarna1 — revenue?
- Over 2 years (2023 to 2025), PTC Therapeutics's translarna1 — revenue has grown at a -15.9% compound annual growth rate (CAGR), from $332.75M to $235.3M.
- What does translarna1 — revenue mean?
- This metric represents the total net revenue generated from the sale of the Translarna product line, excluding any assessed taxes. It reflects the commercial performance and market adoption of this specific therapeutic asset within the company's rare disorder portfolio. Tracking this revenue stream is essential for evaluating the product's lifecycle stage and its contribution to the company's overall top-line growth.